Literature DB >> 21556974

Optimal medical therapy, lifestyle intervention, and secondary prevention strategies for cardiovascular event reduction in ischemic heart disease.

Philip Joseph1, Koon Teo.   

Abstract

Medical and lifestyle secondary prevention strategies are essential components for reducing cardiovascular risk, irrespective of whether revascularization is performed. In patients with coronary artery disease (CAD), recent clinical trials have further clarified the management of lipid optimization, renin-angiotensin-aldosterone system inhibition, antiplatelet therapy, and diabetes. Still, many questions remain with regard to optimal secondary prevention strategies in patients with CAD. Despite the significant reductions in cardiovascular morbidity and mortality with secondary prevention therapies demonstrated in clinical trials, long-term adherence to these interventions remains relatively low, with reasons being multifactorial. One promising method to improve compliance is the use of trained nurses/case managers to routinely follow medications, and provide both lifestyle and behavioral counseling. Implementation of this strategy led to significant improvements in medication compliance and risk factor optimization, although these results require confirmation in a randomized clinical study. Given that poor compliance has been associated with worsening cardiovascular outcomes, effective CAD management should include strategies for improving patient adherence to therapies that have proven benefits.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21556974     DOI: 10.1007/s11886-011-0190-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  47 in total

Review 1.  Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Mouaz H Al-Mallah; Imad M Tleyjeh; Ahmed A Abdel-Latif; W Douglas Weaver
Journal:  J Am Coll Cardiol       Date:  2006-03-29       Impact factor: 24.094

2.  Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?

Authors:  David J Maron; William E Boden; William S Weintraub; Karen J Calfas; Robert A O'Rourke
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-02

3.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

4.  Long-term adherence with cardiovascular drug regimens.

Authors:  Sonali P Kulkarni; Karen P Alexander; Barbara Lytle; Gerardo Heiss; Eric D Peterson
Journal:  Am Heart J       Date:  2006-01       Impact factor: 4.749

5.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

7.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

8.  Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease.

Authors:  P Michael Ho; David J Magid; Susan M Shetterly; Kari L Olson; Thomas M Maddox; Pamela N Peterson; Frederick A Masoudi; John S Rumsfeld
Journal:  Am Heart J       Date:  2008-04       Impact factor: 4.749

9.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.

Authors:  Amit Kumar; Gregg C Fonarow; Kim A Eagle; Alan T Hirsch; Robert M Califf; Mark J Alberts; William E Boden; P Gabriel Steg; Mingyuan Shao; Deepak L Bhatt; Christopher P Cannon
Journal:  Crit Pathw Cardiol       Date:  2009-09
View more
  2 in total

1.  3.0-T MR imaging of intracoronary local delivery of motexafin gadolinium into coronary artery walls.

Authors:  Yanfeng Meng; Jinnan Wang; Jihong Sun; Feng Zhang; Patrick Willis; Jiakai Li; Han Wang; Tong Zhang; Stephanie Soriano; Bensheng Qiu; Xiaoming Yang
Journal:  Radiology       Date:  2013-03-19       Impact factor: 11.105

2.  Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study.

Authors:  Pauliina Pisto; Merja Santaniemi; Risto Bloigu; Olavi Ukkola; Y Antero Kesäniemi
Journal:  BMJ Open       Date:  2014-03-20       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.